Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Parallel investigational arm in Phase 3 DAYBREAK vs aflibercept; enrollment completed.
KSI-101
Phase 3 · ActiveModality: bispecific protein (100 mg/mL)
Target IL-6 and VEGF
Indications
Macular edema secondary to inflammation (MESI)(Phase 3)
Catalysts
— December 2026
— 2Q 2027
Status note PEAK and PINNACLE Phase 3 studies enrolling MESI subjects.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.